| Open Document File Size: 2,50 MBShare Result on Facebook
City Utrecht / St-Legier / / Company IgG / Pall / Caliper Life Sciences / Roche Diagnostics / Millipore / Sigma-Aldrich / GraphPad Software / Agilent / Scale Process 20 g/L Manufacturing / Tosoh / Qiagen / HP / GE Healthcare / Dionex Corp. / Bio-Rad / / Country Switzerland / Netherlands / / / IndustryTerm molecular devices / bispecific end product / stock solution / bsIgG1 product / upstream manufacturing approaches / antibody manufacturing techniques / analytical systems / manufacturing-scale / chemical crosslinking5 / end product / cell selection protocols / final solution / stop solution / bispecific product / clinical manufacturing scale / meet manufacturing requirements / biopharmaceutical industry / large-scale manufacturing / manufacturing processes / heterodimer product / mM stock solution / antibody manufacturing / final product / cell line development protocols / manufacturing / polypeptide chain / manufacturing site / manufacturing-scale processes / buffer solutions / manufacturing platforms / stopped by adding stop solution / / MedicalCondition DF / acetate dissociation / MS / dissociation / dehydration / / OperatingSystem Cygnus / / Organization UV CD / U.S. Securities and Exchange Commission / US Federal Reserve / L PBS / / Person Brooklyn Park / Baxter Healthcare / Lot Size / / / Position producer / CHO forward / reporter / / Product sodium chloride / manganese chloride / DNeasy Blood / A280 / DV / / ProgrammingLanguage C / J / / ProvinceOrState North Dakota / / Technology Cygnus technologies / protein engineering / ADC / antibodies / cell line development protocols / electrophoresis system / Maximum Entropy algorithm / recombination / cell selection protocols / / URL www.landesbioscience.com / http /
SocialTag |
REPORT mAbs 5:6, 962–973; November/December 2013; © 2013 Landes Bioscience Production of stable bispecific IgG1 by controlled Fab-arm exchange